Mogamulizumab shows real-world effectiveness in rare skin lymphomas

Mogamulizumab shows real-world effectiveness in rare skin lymphomas

Kyowa Kirin International has reported final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary syndrome (SS) in routine clinical practice.

MF and SS are rare forms of cutaneous T-cell lymphoma, a type of non-Hodgkin lymphoma that affects the skin. Symptoms may include persistent rashes, changes in skin colour, plaques and tumours.

The study included 109 patients treated across 18 centres in Germany, with a median follow-up of 25.2 months.

Key findings included:

🔹 62.4% of patients achieved an overall response;

🔹 median progression-free survival was 20.2 months;

🔹 median time to the next treatment was 14.9 months;

🔹 meaningful responses were also seen in clinically challenging patient subgroups.

Patients also reported improvements in quality of life, with notable improvements in skin-related quality-of-life scores after 12 months.

The safety profile was generally consistent with previous Phase III data. However, some patients experienced serious treatment-related adverse events that led to treatment discontinuation.

Researchers said the findings provide useful evidence on how mogamulizumab performs outside controlled clinical trials and in everyday medical practice.